Liechtenstein-based biotech company reports significant lifespan extension in C. elegans and advances toward preclinical development with CRO partners We built a compound series with the strongest reported SIRT6 activation in the literature. The patent filing protects this work as we move into preclinical development.” — Andraz Zurman, Co-Founder, Virella Ltd SCHAAN, LIECHTENSTEIN, April 3, 2026 / EINPresswire.com / -- Virella Ltd, a European biotech company developing small-molecule SIRT6 acti

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a la

LOS ANGELES, April 3, 2026 /PRNewswire/ -- As tick activity increases during the warmer months, Better Life Science is highlighting prevention, early response and access to at-home Lyme disease testing through its Tick Bite Hero brand. With more people spending time outdoors this spring, Better Life Science is reminding consumers that tick bites often go unnoticed, making prevention and fast response especially important. Public health guidance recommends using repellent, checking for ticks aft

ORLANDO, Fla., April 3, 2026 /PRNewswire/ -- During the second annual National Youth Heart Screening Day, more than 50 children and young adults were identified at risk for sudden cardiac arrest (SCA) through a nationwide effort led by Parent Heart Watch. Held during Heart Month, the initiative brought together 16 organizations and 3 co-partners across 21 sites in 14 states, providing free heart screenings and life-saving education nationwide. The effort was supported by Cardiac Insight and Liqu

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. “We are thrilled to welcome Kim to our Board of Directors,” said David Meek

ROSEMONT, Ill., April 3, 2026 /PRNewswire/ -- Oral and oropharyngeal cancers account for roughly one death every hour in the United States, yet outcomes improve substantially when the disease is found early. During April's Oral Cancer Awareness Month, the American Association of Oral and Maxillofacial Surgeons (AAOMS) is encouraging the public to take two simple steps: perform a monthly self-exam and schedule regular screenings with a healthcare provider. National statistics illustrate why aware

BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded an inducement grant on April 1, 2026 to one new employee under Bicara’s 2026 Inducement Plan as a material inducement to employment. The employee received a non-qualified stock option to purchase 44,175 shares of Bicara’s common stock, par value $0.000

DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 300,000 shares of the C

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company’s new Chief Business Officer. The inducement award consisted of non-qualif

FREDERICK, Md., April 3, 2026 /PRNewswire/ -- OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and expression solutions, today announced a strategic partnership to deliver industry-leading cell line development services for biopharmaceutical companies worldwide. Continue Reading OneCyte and Kemp Proteins collaboration This collaboration brings together OneCyte's proprietary single-cell platform f